CDX011-04, A Randomized Multicenter Pivotal Study of CDX-011 in Patients with Metastatic, gpNMB Over-expressing, Triple Negative Breast Cancer (The METRIC Study)

Cancer - Breast

18 years and older; Diagnosed with metastatic (cancer that has spread) triple negative (does not have hormone receptors ER or PR or HER2) breast cancer; breast cancer confirmed to express gpNMB; no more than two prior chemotherapy treatments for advanced breast cancer; prior chemo must have contained an anthracycline (e.g. doxorubicin or Doxil) and a taxane (e.g. Taxol)

Tiffany Pearce